A therapy that filters blood to remove a specific protein implicated in the disease's cascade of harm
For generations, preeclampsia has confronted medicine with a cruel dilemma — endanger the mother or endanger the child — and medicine has largely answered with silence. Now, researchers in California have published early evidence of a blood-filtering therapy that removes the specific protein driving the disease's destruction, suggesting that a third path between those two grim choices may at last be within reach. The findings, published in Nature, are preliminary, but they arrive into a void where no targeted treatment has ever existed, and that absence alone gives them weight.
- Preeclampsia strikes millions of pregnancies each year and remains a leading killer of mothers in developed nations, yet medicine has never had a way to reverse its underlying damage — only to manage the moment of crisis.
- The tension at the heart of every severe case is unbearable: continuing the pregnancy risks seizure, stroke, and organ failure for the mother, while early delivery condemns a premature infant to its own fight for survival.
- California researchers have designed a therapy that runs a patient's blood through an external filter to strip out sFlt-1, the protein that accumulates to toxic levels and triggers the disease's cascade of vascular destruction.
- Early pilot trial results show reduced sFlt-1 levels, extended pregnancies, and improved outcomes for both mothers and infants — enough to earn publication in Nature and serious attention from the global medical community.
- The path ahead requires larger randomized trials to confirm safety and efficacy, but if they succeed, a treatment that did not exist a few years ago could become a routine intervention that saves thousands of lives annually.
Preeclampsia kills without warning. Blood pressure surges, organs falter, and both mother and child are placed in jeopardy — yet for decades, medicine's only real answer has been early delivery, a choice that rescues one life by imperiling another. Premature infants land in neonatal units while their mothers recover from a condition that could not be stopped, only interrupted.
The disease's engine, researchers now understand, is a protein called sFlt-1. In preeclampsia, it accumulates to dangerous levels, corrupting blood vessels and igniting the inflammation that defines the condition. A team at California institutions designed a therapy to confront it directly: an extracorporeal blood filter that draws blood outside the body, captures sFlt-1, and returns the cleaned blood to circulation. It is a mechanical intervention — precise, reversible, and unlike anything that has been tried before.
The pilot trial focused on very preterm preeclampsia, cases arising before 32 weeks, where the stakes are at their highest. Early results showed that the therapy reduced sFlt-1 levels and appeared to extend pregnancies while improving outcomes for both mothers and infants. The findings were published in Nature, a signal that the scientific community considers the approach worthy of serious pursuit.
The therapy is not a cure. It does not explain why sFlt-1 rises in the first place. But by interrupting the protein's accumulation, it may buy critical time — shifting the impossible calculus that has long defined this disease. Larger randomized trials are needed before any of this reaches clinical practice, but the work represents something rare: a plausible third option where medicine has only ever offered two.
Preeclampsia kills. It strikes without warning during pregnancy, sending blood pressure soaring, damaging organs, threatening both mother and child. For decades, doctors have had few options beyond early delivery—a choice that trades one danger for another, leaving premature infants fighting for survival in neonatal units while their mothers recover from a condition medicine could not prevent. Now, researchers at California institutions have published results from a pilot trial suggesting a different path forward: a therapy that filters blood to remove a specific protein implicated in the disease's cascade of harm.
The protein in question is soluble Fms-like tyrosine kinase 1, abbreviated sFlt-1. In preeclampsia, this protein accumulates to dangerous levels, triggering the vascular dysfunction and inflammation that define the condition. The California team designed a treatment to target it directly—using extracorporeal blood filtration, essentially running a patient's blood through a specialized filter outside the body to capture and remove sFlt-1, then returning the cleaned blood to circulation. It is a mechanical intervention, precise and reversible, quite different from the pharmaceutical approaches that have largely failed against this disease.
The pilot trial enrolled patients with very preterm preeclampsia, the most severe form, occurring before 32 weeks of gestation. These are the cases where the stakes are highest: continuing the pregnancy risks maternal organ failure and death; delivering the baby risks profound prematurity. The researchers found that the blood-filtering therapy reduced sFlt-1 levels in treated patients and, in early results, appeared to extend pregnancies and improve outcomes for both mothers and infants. The findings were published in Nature, lending them credibility within the scientific community and signaling that this approach warrants serious investigation.
What makes this work significant is not just the mechanism but the gap it addresses. Preeclampsia is common—it affects millions of pregnancies worldwide—and it remains a leading cause of maternal death in developed countries and a major driver of preterm birth. Current management relies on monitoring and delivery timing; there is no cure, no way to reverse the underlying pathology. Women diagnosed with severe preeclampsia face an impossible calculus: stay pregnant and risk seizure, stroke, kidney failure, or liver rupture; deliver early and accept the complications of prematurity for the child. Some pregnancies end in fetal death. Some end in maternal death. The condition has resisted easy solutions.
The California researchers' approach is not a cure in the traditional sense. It does not address why sFlt-1 levels rise in the first place. But by removing the protein, it may interrupt the cascade of damage, buying time for the pregnancy to advance and reducing the severity of maternal illness. If larger trials confirm these early results, the therapy could shift how doctors manage very preterm preeclampsia—offering a third option between the grim choice of continuing a dangerous pregnancy or delivering a dangerously premature infant.
The work is preliminary. Pilot trials are small, and results must be validated in larger populations before any therapy reaches clinical practice. But the publication in Nature and the attention from outlets ranging from The Economist to Science News suggests the medical community recognizes the potential. The next phase will be larger randomized controlled trials to confirm efficacy, establish safety, and determine which patients benefit most. If those trials succeed, a treatment that seemed impossible a few years ago could become routine, transforming outcomes for thousands of women and their babies each year.
Notable Quotes
The therapy may interrupt the cascade of damage, buying time for the pregnancy to advance and reducing the severity of maternal illness— California researchers, based on pilot trial findings
The Hearth Conversation Another angle on the story
Why does preeclampsia happen in the first place? What causes sFlt-1 to spike?
That's still not fully understood. The placenta seems to be the source—something about how it develops in preeclampsia triggers the release of this protein. But the exact mechanism remains a mystery. The therapy doesn't solve that mystery; it just removes the protein once it's there.
So this is damage control, not prevention.
Exactly. You can't stop the placenta from making sFlt-1, but you can filter it out of the blood before it destroys the mother's blood vessels and organs. It's like treating a fire rather than preventing the fire.
Why hasn't anyone tried this before?
They have, in different forms. But this particular approach—using extracorporeal filtration to target sFlt-1 specifically—is newer. And it required the right combination of technology, understanding of the disease, and willingness to try something mechanically invasive when drugs had failed.
What happens to the women in the trial after treatment ends?
That's crucial data we don't have yet from a pilot. Do they relapse? Do they need repeated sessions? Does the benefit last? Those are the questions the larger trials need to answer.
If this works, how quickly could it reach patients?
If the next phase of trials is successful, probably three to five years. But that assumes funding, regulatory approval, and manufacturing scale-up all move smoothly. Medical breakthroughs rarely move as fast as we'd like.